BioMarin Pharmaceutical | BMRN - Equity Capital And Reserves


BioMarin Pharmaceutical reported $6.32B in Equity Capital and Reserves for its fiscal quarter ending in June of 2026.





Equity Capital And Reserves Change Date
Acadia Pharmaceuticals USD 1.31B 58.54M Jun/2026
Agios Pharmaceuticals USD 1.03B 83.09M Jun/2026
Alnylam Pharmaceuticals USD 1.35B 278.74M Jun/2026
Amgen USD 11.69B 2.5B Jun/2026
Bayer EUR 29.71B 863M Jun/2026
Biogen USD 18.85B 196.3M Jun/2026
BioMarin Pharmaceutical USD 6.32B 109.58M Jun/2026
Gilead Sciences USD 11.74B 11.77B Jun/2026
Incyte USD 6.34B 721.58M Jun/2026
Insmed USD 757.49M 52.64M Jun/2026
Ionis Pharmaceuticals USD 439.74M 51.68M Jun/2026
Moderna USD 6.76B 647M Jun/2026
Neurocrine Biosciences USD 3.69B 286.2M Jun/2026
PTC Therapeutics USD -165.36M 15.1M Jun/2026
Puma Biotechnology USD 115.27M 10.55M Sep/2025
Regeneron Pharmaceuticals USD 31.71B 287.8M Jun/2026
Roche Holding CHF 32.69B 1.11B Jun/2026
Sangamo BioSciences USD 19.6M 14.7M Jun/2025
Sanofi EUR 73.14B 1.43B Mar/2026
Sarepta Therapeutics USD 1.53B 22.7M Jun/2026
Ultragenyx Pharmaceutical USD -291M 55M Jun/2026
United Therapeutics USD 6.4B 499.2M Jun/2026
Vertex Pharmaceuticals USD 20.25B 886M Jun/2026